small molecule

XEPI

OZENOXACIN

Loss of exclusivityJanuary 2032latest FDA-listed patent expiry
CompanyLNHC INC

Drug detail

Brand nameXEPI
Active ingredientOZENOXACIN
Strength1%
Dosage formCREAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalDecember 2017
Marketing statusDISCN

Listed patents

PatentExpiresType
9180200January 2032product
9399014December 2029use U-805

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

XEPI patent cliff — loss of exclusivity January 2032 | CliffBio